Cerevel Therapeutics Holdings, Inc.

Welcome to the Cerebral Therapeutics Fourth Quarter and Full Year 2020 Financial Results Conference Call. At this time, all participants are in listen-only mode. Later, you will have the opportunity to ask questions during the Q&A portion of the call. Please note that this call may be recorded. I will now hand the call over to Matt Calistri, Vice President of Investor Relations.

Thank you. Good morning, everyone. We appreciate you joining us for our Fourth Quarter and Full Year 2020 earnings call. On today's call, you will be hearing from Dr. Tony Coles, our Chief Executive Officer, Dr. Ray Sanchez, our Chief Medical Officer, Dr. John Renger, our Chief Scientific Officer, and Kathy Yee, our Chief Financial Officer. During our call today, please refer to our press release from this morning detailing our 2020 performance, as well as our updated corporate presentation, both of which are available on our website. I would like to remind you that we will be making forward-looking statements that reflect our current views related to our financial performance, future events, and industry and market conditions, as well as forward-looking statements including the potential attributes and benefits of our product candidates and the format and timing of Cereval's product development activities and clinical trials. We strongly encourage you to review the information that we file with the SEC regarding specific risks and uncertainties. I will now hand it over to Dr. Tony Coles, chairperson and CEO of Ceravel, to provide an overview of our achievements and outlook.

Thanks, Matt, and good morning, everyone. Thank you all for joining us for our first quarterly results call as a public company. I look forward to outlining our numerous achievements from 2020 and our outlook for this year. Here at Ceravel, we remain steadfast in our goal to become the premier neuroscience company. As you may recall, Ceregal was founded in 2018 with a rich and deep portfolio of 11 small molecule programs that have benefited for more than 10 years and over a billion dollars of investment at Pfizer. Within this portfolio, we now have five clinical programs that we expect will generate up to eight data readouts by the end of 2023 as we continue to leverage our receptor subtype targeting approach to addressing some of the most vexing questions in neuroscience. In the first quarter of 2020, in response to the onset of the COVID-19 pandemic, we paused enrollment in all of our trials as patient safety is always our top priority. I'm proud to say that thanks to the hard work and creativity of our team, we have been able to safely reinitiate and start dosing in all of our current clinical trials, which includes three phase three trials for tevapidon and Parkinson's, phase one and two trials for our gabapam, derigabat, and anxiety and epilepsy respectively, and our phase 1B trial in schizophrenia for our M4 selective positive allosteric modulator, CVL231. Meanwhile, we have continued to expand our capabilities as a company growing our organization from approximately 65 employees at the end of 2019 to just over 100 employees by the end of 2020, with the majority of that growth in our REV departments. In the fourth quarter of 2020, we completed a groundbreaking GoPublic transaction. The business combination with ARIA 2, a special purpose acquisition company for SPAC, along with a pipe transaction that together yielded net proceeds of $440 million. This deal enabled advancement of our lead programs and provided us with a cash runway into 2023. This year, our momentum continues. We have two key data readouts coming later this year for CVL 231 and Duragabat. We're opening our 60,000 square foot Cambridge Crossing headquarters complete with over 15,000 square feet of lab space to enable speedy and efficient drug discovery and the exploration of new targets. We have multiple INDs forthcoming for preclinical programs, and we're focused on leveraging enabling technologies such as gene editing and artificial intelligence to identify new drug targets for neuroscience diseases. We're proud of how far we've come at Cerevel in such a short period of time, as we seek to transform what is possible in neuroscience and bring new treatment options to patients with challenging diseases like schizophrenia, anxiety, epilepsy, and Parkinson's. To provide additional detail on our clinical efforts, I'd now like to ask Dr. Ray Sanchez, our Chief Medical Officer, to review our pipeline progress. Ray?